SpectraGenics Inc., a Pleasanton, Calif.-based developer of OTC consumer cosmetic medical devices, has called down around $30 million of a $37 million Series E round, according to a regulatory filing. Aisling Capital led the round, and was joined by return backers like De Novo Ventures, Technology Partners, GVC (